Embryonic stem cell therapy-diabetes - Lineage Cell Therapeutics/Wisconsin Alumni Research Foundation
Alternative Names: GRNIC-1; IC-1Latest Information Update: 03 Nov 2021
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Asterias Biotherapeutics
- Class Stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 31 Jul 2019 BioTime is now called Lineage Cell Therapeutics
- 11 Mar 2019 Asterias Biotherapeutics has been acquired and merged into BioTime
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Intralesional)